Clinical Trial Update: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes evaluating a combination of tafasitamab, lenalidomide, and rituximab in frontline diffuse large B-cell lymphoma patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)
• tafasitamab (tafasitamab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: DLBCL | Phase 2 | Status: ACTIVE_NOT_RECRUITING